CRISM Therapeutics Corporation Total Liabilities
CRISM Therapeutics Corporation total liabilities. Based on the latest financial reports, CRISM Therapeutics Corporation (CRTX) has total liabilities worth GBX343.00K GBX (≈ $41.73 USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of CRISM Therapeutics Corporation to evaluate the company's liquid asset resilience ratio.
Total Liabilities of CRISM Therapeutics Corporation (2006–2025)
Total liabilities of CRISM Therapeutics Corporation from 2006 to 2025. This chart illustrates how CRISM Therapeutics Corporation's total liabilities have evolved over time, based on quarterly financial data.
CRISM Therapeutics Corporation Competitors by Total Liabilities
The table below lists competitors of CRISM Therapeutics Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
INSURAGUEST TECHN. INC.
F:4JG
|
Germany | €703.54K |
|
PENTAL LTD
F:81B
|
Germany | €2.42 Million |
|
Tanfield Group PLC
LSE:TAN
|
UK | GBX582.00K |
|
Fusion Antibodies PLC
LSE:FAB
|
UK | GBX1.09 Million |
|
Oxurion NV
BR:OXUR
|
Belgium | €16.98 Million |
|
SEEEN PLC
LSE:SEEN
|
UK | GBX2.22 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down CRISM Therapeutics Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CRTX asset base.
Liquidity & Leverage Metrics
CRISM Therapeutics Corporation Total Liabilities Ratios Explained
CRISM Therapeutics Corporation total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CRISM Therapeutics Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CRISM Therapeutics Corporation (2006–2025)
The table below shows the annual total liabilities of CRISM Therapeutics Corporation from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | GBX381.00K ≈ $46.36 |
+11.73% |
| 2024-12-31 | GBX341.00K ≈ $41.49 |
-62.94% |
| 2023-12-31 | GBX920.19K ≈ $111.96 |
+20.18% |
| 2022-12-31 | GBX765.65K ≈ $93.16 |
-32.06% |
| 2021-12-31 | GBX1.13 Million ≈ $137.12 |
+6.93% |
| 2020-12-31 | GBX1.05 Million ≈ $128.24 |
+23.67% |
| 2019-12-31 | GBX852.24K ≈ $103.69 |
-69.17% |
| 2018-12-31 | GBX2.76 Million ≈ $336.30 |
+192.80% |
| 2017-12-31 | GBX944.00K ≈ $114.86 |
-75.65% |
| 2016-12-31 | GBX3.88 Million ≈ $471.72 |
+446.67% |
| 2015-12-31 | GBX709.20K ≈ $86.29 |
+74.25% |
| 2014-12-31 | GBX407.00K ≈ $49.52 |
+448.16% |
| 2013-12-31 | GBX74.25K ≈ $9.03 |
+1.42% |
| 2012-12-31 | GBX73.21K ≈ $8.91 |
-28.23% |
| 2011-12-31 | GBX102.00K ≈ $12.41 |
-6.93% |
| 2010-12-31 | GBX109.60K ≈ $13.34 |
-62.13% |
| 2009-12-31 | GBX289.43K ≈ $35.21 |
-0.92% |
| 2008-12-31 | GBX292.12K ≈ $35.54 |
+66.62% |
| 2007-12-31 | GBX175.32K ≈ $21.33 |
+1016.29% |
| 2006-12-31 | GBX15.71K ≈ $1.91 |
-- |
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs in the British Virgin Islands. The company's lead product is ChemoSeed, which can be implanted directly into the tumour or the resection margin following the removal of a tumour. It also provides formulation and cons… Read more